Recent advance drug discovery: innovative approaches targeted therapies
Abstract
Drug discovery is a dynamic field constantly evolving with the aim of identifying novel therapeutic agents to combat various diseases. In this review, we present an overview of recent advances in drug discovery, highlighting innovative approaches and targeted therapeutics that have emerged in the last few years. The review covers a range of cutting-edge techniques and strategies used in drug design and development, including artificial intelligence and machine learning-based approaches, high-throughput screening, and rational drug design therapeutic agents to combat various diseases. In this review, we present an overview of recent advances in drug discovery.
Keywords:
Drug Discovery, Innovative Approaches, Targeted Therapeutics, Artificial Intelligence, Machine Learning, High-Throughput Screening, Rational Drug Design, Personalized Medicine, Precision Treatments
Downloads
Download data is not yet available.
References
1. Swinney DC, Anthony J. How were new medicines discovered?. Nature reviews Drug discovery. 2011 Jul;10(7):507-19
https://doi.org/10.1186/s43094-020-00047-9
2. Nama S, Chandu BR, Awen BZ, Khagga M. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Tropical Journal of Pharmaceutical Research. 2011;10(4):491-7.
https://doi.org/10.1186/s43094-020-00047-9
3. Piachaud, B. S. (2002). Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience. Technovation, 22(2), 81-90.Piachaud, B. S. (2002). Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience. Technovation, 22(2), 81-90
https://doi.org/10.1186/s43094-020-00047-9
4. Collin, C. B., Gebhardt, T., Golebiewski, M., Karaderi, T., Hillemanns, M., Khan, F. M., ... & Kuepfer, L. (2022). Computational models for clinical applications in personalized medicine—guidelines and recommendations for data integration and model validation. Journal of personalized medicine, 12(2), 166.
https://doi.org/10.3390/ pharmaceutics16030332
5. Baluguri, Pavan Kumar; Nama, Srikanth; Chandu, Babu Rao; Sakala, Bhargavi; LC/MS: AN ESSENTIAL TOOL IN DRUG DEVELOPMENT International Journal of Advances in Pharmaceutical Analysis 1 224-37 2012https://doi.org/10.3390/ pharmaceutics16030332.
6. Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, Gonzalez D. Precision dosing priority criteria: drug, disease, and patient population variables. Frontiers in pharmacology. 2020 Apr 22;11:420
https://doi.org/10.3390/ pharmaceutics16030332
7. El-Alti, L., Sandman, L., & Munthe, C. (2019). Person centered care and personalized medicine: irreconcilable opposites or potential companions?. Health Care Analysis, 27, 45-59. https://doi.org/10.3390/ pharmaceutics16030332
8. Vicente, A. M., Ballensiefen, W., & Jönsson, J. I. (2020). How personalised medicine will transform healthcare by 2030: the ICPerMed vision. Journal of translational medicine, 18, 1-4 https://doi.org/10.3390/ pharmaceutics16030332
9. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent..
https://doi.org/10.1177/1087057113501199
10. Gindi S, Methra T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and invitro anti-oxidant activity of leaves of Ageratum conyzoides in rat. World J. Pharm. Pharm. Sci. 2013 Feb 8;2:636-49.
https://doi.org/10.1177/1087057113501199
11. Cummings, M. D., DesJarlais, R. L., Gibbs, A. C., Mohan, V., & Jaeger, E. P. (2005). Comparison of automated docking programs as virtual screening tools. Journal of medicinal chemistry, 48(4), 962-976
https://doi.org/10.1177/1087057113501199
12. Baiardini, I., & Heffler, E. (2019). The patient-centered decision system as per the 4Ps of precision medicine. In Implementing precision medicine in best practices of chronic airway diseases (pp. 147-151). Academic Press.
https://doi.org/10.3390/ pharmaceutics16030332
13. Gameiro, G. R., Sinkunas, V., Liguori, G. R., & Auler-Júnior, J. O. C. (2018). Precision medicine: changing the way we think about healthcare. Clinics, 73, e723..
https://doi.org/10.3390/ pharmaceutics16030332
14. Delpierre, C., & Lefèvre, T. (2023). Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Frontiers in Sociology, 8, 1112159.
https://doi.org/10.3390/ pharmaceutics16030332.
15. Leil, T. A., Kasichayanula, S., Boulton, D. W., & LaCreta, F. (2014). Evaluation of 4β‐Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model. CPT: pharmacometrics & systems pharmacology, 3(6), 1-10
https://doi.org/10.3390/ pharmaceutics16030332
16. Diczfalusy, U., Nylén, H., Elander, P., & Bertilsson, L. (2011). 4β‐hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. British journal of clinical pharmacology, 71(2), 183-189.
https://doi.org/10.3390/ pharmaceutics16030332
17. Kathman, S. J., Williams, D. H., Hodge, J. P., & Dar, M. (2007). A Bayesian Population PK–PD Model of Ispinesib‐induced Myelosuppression. Clinical Pharmacology & Therapeutics, 81(1), 88-94.
https://doi.org/10.3390/ pharmaceutics16030332
18. Dara SR. An Overview of the Use of Natural Indicators in Acid-Base Titrations. UPI Journal of Pharmaceutical, Medical and Health Sciences. 2024 Jul 23:29-35..
https://doi.org/10.3390/ pharmaceutics16030332
19. Leil, T. A., Kasichayanula, S., Boulton, D. W., & LaCreta, F. (2014). Evaluation of 4β‐Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model. CPT: pharmacometrics & systems pharmacology, 3(6), 1-10.
https://doi.org/10.3390/ pharmaceutics16030332
20. Premalatha, A., Bora, M. A., Bhoomandla, S., & Nakkella, A. K. ISSN 2063-5346 Recent Advances in Drug Discovery: Innovative Approaches and Targeted https://doi.org/10.1177/1087057113501199
21. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews, 65(1), 36-48. https://doi.org/10.1177/1087057113501199
22. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2020). Nanocarriers as an emerging platform for cancer therapy. Nano-enabled medical applications, 61-91.
https://doi.org/10.1177/1087057113501199
23. Niazi, S. K. (2023). The Dawn of in vivo gene editing era: A Revolution in the making. Biologics, 3(4), 253-295.
https://doi.org/10.1177/1087057113501199
https://doi.org/10.1186/s43094-020-00047-9
2. Nama S, Chandu BR, Awen BZ, Khagga M. Development and validation of a new RP-HPLC method for the determination of aprepitant in solid dosage forms. Tropical Journal of Pharmaceutical Research. 2011;10(4):491-7.
https://doi.org/10.1186/s43094-020-00047-9
3. Piachaud, B. S. (2002). Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience. Technovation, 22(2), 81-90.Piachaud, B. S. (2002). Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience. Technovation, 22(2), 81-90
https://doi.org/10.1186/s43094-020-00047-9
4. Collin, C. B., Gebhardt, T., Golebiewski, M., Karaderi, T., Hillemanns, M., Khan, F. M., ... & Kuepfer, L. (2022). Computational models for clinical applications in personalized medicine—guidelines and recommendations for data integration and model validation. Journal of personalized medicine, 12(2), 166.
https://doi.org/10.3390/ pharmaceutics16030332
5. Baluguri, Pavan Kumar; Nama, Srikanth; Chandu, Babu Rao; Sakala, Bhargavi; LC/MS: AN ESSENTIAL TOOL IN DRUG DEVELOPMENT International Journal of Advances in Pharmaceutical Analysis 1 224-37 2012https://doi.org/10.3390/ pharmaceutics16030332.
6. Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, Gonzalez D. Precision dosing priority criteria: drug, disease, and patient population variables. Frontiers in pharmacology. 2020 Apr 22;11:420
https://doi.org/10.3390/ pharmaceutics16030332
7. El-Alti, L., Sandman, L., & Munthe, C. (2019). Person centered care and personalized medicine: irreconcilable opposites or potential companions?. Health Care Analysis, 27, 45-59. https://doi.org/10.3390/ pharmaceutics16030332
8. Vicente, A. M., Ballensiefen, W., & Jönsson, J. I. (2020). How personalised medicine will transform healthcare by 2030: the ICPerMed vision. Journal of translational medicine, 18, 1-4 https://doi.org/10.3390/ pharmaceutics16030332
9. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent..
https://doi.org/10.1177/1087057113501199
10. Gindi S, Methra T, Chandu BR, Boyina R, Dasari V. Antiurolithiatic and invitro anti-oxidant activity of leaves of Ageratum conyzoides in rat. World J. Pharm. Pharm. Sci. 2013 Feb 8;2:636-49.
https://doi.org/10.1177/1087057113501199
11. Cummings, M. D., DesJarlais, R. L., Gibbs, A. C., Mohan, V., & Jaeger, E. P. (2005). Comparison of automated docking programs as virtual screening tools. Journal of medicinal chemistry, 48(4), 962-976
https://doi.org/10.1177/1087057113501199
12. Baiardini, I., & Heffler, E. (2019). The patient-centered decision system as per the 4Ps of precision medicine. In Implementing precision medicine in best practices of chronic airway diseases (pp. 147-151). Academic Press.
https://doi.org/10.3390/ pharmaceutics16030332
13. Gameiro, G. R., Sinkunas, V., Liguori, G. R., & Auler-Júnior, J. O. C. (2018). Precision medicine: changing the way we think about healthcare. Clinics, 73, e723..
https://doi.org/10.3390/ pharmaceutics16030332
14. Delpierre, C., & Lefèvre, T. (2023). Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Frontiers in Sociology, 8, 1112159.
https://doi.org/10.3390/ pharmaceutics16030332.
15. Leil, T. A., Kasichayanula, S., Boulton, D. W., & LaCreta, F. (2014). Evaluation of 4β‐Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model. CPT: pharmacometrics & systems pharmacology, 3(6), 1-10
https://doi.org/10.3390/ pharmaceutics16030332
16. Diczfalusy, U., Nylén, H., Elander, P., & Bertilsson, L. (2011). 4β‐hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. British journal of clinical pharmacology, 71(2), 183-189.
https://doi.org/10.3390/ pharmaceutics16030332
17. Kathman, S. J., Williams, D. H., Hodge, J. P., & Dar, M. (2007). A Bayesian Population PK–PD Model of Ispinesib‐induced Myelosuppression. Clinical Pharmacology & Therapeutics, 81(1), 88-94.
https://doi.org/10.3390/ pharmaceutics16030332
18. Dara SR. An Overview of the Use of Natural Indicators in Acid-Base Titrations. UPI Journal of Pharmaceutical, Medical and Health Sciences. 2024 Jul 23:29-35..
https://doi.org/10.3390/ pharmaceutics16030332
19. Leil, T. A., Kasichayanula, S., Boulton, D. W., & LaCreta, F. (2014). Evaluation of 4β‐Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model. CPT: pharmacometrics & systems pharmacology, 3(6), 1-10.
https://doi.org/10.3390/ pharmaceutics16030332
20. Premalatha, A., Bora, M. A., Bhoomandla, S., & Nakkella, A. K. ISSN 2063-5346 Recent Advances in Drug Discovery: Innovative Approaches and Targeted https://doi.org/10.1177/1087057113501199
21. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews, 65(1), 36-48. https://doi.org/10.1177/1087057113501199
22. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2020). Nanocarriers as an emerging platform for cancer therapy. Nano-enabled medical applications, 61-91.
https://doi.org/10.1177/1087057113501199
23. Niazi, S. K. (2023). The Dawn of in vivo gene editing era: A Revolution in the making. Biologics, 3(4), 253-295.
https://doi.org/10.1177/1087057113501199
Published
30/06/2025
Statistics
25 Views | 40 Downloads
Citatons
How to Cite
Chitla, S. L. “Recent Advance Drug Discovery: Innovative Approaches Targeted Therapies”. International Journal of Alternative and Complementary Medicine, Vol. 6, no. 1, June 2025, pp. 1-5, https://saapjournals.org/index.php/ijacm/article/view/711.
Issue
Section
Review Article
Copyright © Author(s) retain the copyright of this article.
.